Oxcarbazepine API Market Sees Price Surge; Analysts Predict Continued Growth in Early 2026

Oxcarbazepine API Market Sees Price Surge; Analysts Predict Continued Growth in Early 2026

Honoré de Balzac 20-Jan-2026

The global market for the pharmaceutical sector experienced an increasing trend in the price of the Oxcarbazepine Active Pharmaceutical Ingredient for the last month of 2025, and it is expected to continue in January 2026. The trend is contrary to what was experienced in the pharmaceutical sector in the middle of 2025, which was driven by the tightening of supply chains, rising production costs, and global trade trends. The export price for the main exporting countries of India and China has been increasing due to prudent selling, along with rising downstream oxcarbazepine demands for the last month of the year. Rising costs in terms of feed stock, solvents, and energy have made it imperative for the sector to revise their pricing strategies in order to maintain their profit margins. On the other hand, in terms of imports, buyers across the global market are now facing higher landing costs owing to freight inflation, upstream material dependencies, specifically in China, and minimum import prices. Forecasts indicate that oxcarbazepine prices are likely to remain under pressure in the first quarter of 2026 owing to rising demand for neurological formulations.

Selenis has effectively manufactured recycled PET chips using terephthalic acid sourced from Circ®, a textile-to-textile recycler based in Virginia. The chip production took place through a series of batches at Selenis' pilot plant in San-Giorgio, Italy. By utilizing inputs recovered from polycotton textile waste, Selenis has created high-quality PET chip, which has been further processed into DTY yarn. This yarn will play a crucial role in product development as Circ prepares for additional capsule launches. Selenis is leveraging the success of this initial collaboration phase and is committed to advancing towards an offtake partnership to support Circ's inaugural industrial facility. Eduardo Santos, Head of Corporate Strategy at Selenis, remarked that the monomer synthesis showed a performance comparable to virgin terephthalic acid. He expressed optimism about the consistent quality of Circ's monomer output and anticipated future commercial success. Santos pointed out that the Circ partnership complements Selenis's existing mission and goals for a more sustainable textile industry. He further stated their anticipation of expanding upon this collaboration and providing support for Circ's forthcoming commercial production trials.

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.